Bristlecone Advisors LLC Takes Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

Bristlecone Advisors LLC acquired a new position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) in the 3rd quarter, HoldingsChannel.com reports. The firm acquired 50,000 shares of the company’s stock, valued at approximately $208,000.

Several other hedge funds also recently added to or reduced their stakes in SANA. Blue Trust Inc. grew its holdings in Sana Biotechnology by 1,246.6% during the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock worth $55,000 after acquiring an additional 12,154 shares in the last quarter. Algert Global LLC acquired a new position in Sana Biotechnology during the 2nd quarter worth $73,000. XTX Topco Ltd acquired a new position in Sana Biotechnology during the 2nd quarter worth $100,000. Hartline Investment Corp acquired a new position in Sana Biotechnology during the 1st quarter worth $136,000. Finally, Dark Forest Capital Management LP grew its holdings in Sana Biotechnology by 112.0% during the 2nd quarter. Dark Forest Capital Management LP now owns 27,314 shares of the company’s stock worth $149,000 after acquiring an additional 14,430 shares in the last quarter. 88.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on SANA shares. HC Wainwright reduced their price target on shares of Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Citigroup raised their price target on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, August 9th.

Sana Biotechnology Stock Down 1.3 %

Shares of NASDAQ:SANA opened at $3.76 on Monday. The company has a market cap of $832.85 million, a PE ratio of -2.46 and a beta of 1.42. The company’s 50-day moving average price is $4.63 and its 200 day moving average price is $6.11. Sana Biotechnology, Inc. has a fifty-two week low of $2.74 and a fifty-two week high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.04). As a group, equities analysts anticipate that Sana Biotechnology, Inc. will post -1.13 EPS for the current year.

Insiders Place Their Bets

In other news, Director Richard Mulligan sold 150,000 shares of Sana Biotechnology stock in a transaction that occurred on Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total value of $612,000.00. Following the transaction, the director now owns 2,848,121 shares of the company’s stock, valued at $11,620,333.68. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 31.10% of the stock is owned by insiders.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.